Egypt’s Biotech Startup Is Expanding Access to Testing Across Underserved African Markets

Reme-D is turning a Covid-era constraint into a scalable healthcare infrastructure play.

Why You Should Care

Access to reliable diagnostics remains one of the most overlooked constraints in African healthcare systems. Reme-D’s model does not just introduce a new product. It removes one of the system’s core limitations: dependence on cold-chain logistics.

For operators and investors, this signals something bigger. Healthcare innovation in the region is moving from import dependency toward locally engineered solutions that are built for real infrastructure conditions.

Egypt-based biotech startup Reme-D has secured a USD 500,000 investment from the Global Innovation Fund to expand production and distribution of its room-temperature stable molecular diagnostic kits.

The company was originally formed out of a government-backed consortium during the Covid-19 pandemic to address PCR test shortages. Since formally launching in 2022, founder Salma Tammam has repositioned the company toward a broader opportunity: closing diagnostic gaps across Africa.

Traditional PCR testing relies on strict temperature control, making it difficult to deploy in regions with unstable electricity. Reme-D addresses this through freeze-drying techniques and nanotechnology that allow reagents to remain stable at room temperature for months.

This shift is not marginal. It directly impacts cost, access, and scalability. The company reports up to 40% cost reductions compared to imported kits, while maintaining clinical accuracy levels of 95% sensitivity and 98% specificity. Its products are also designed to detect local pathogen strains, an area often underserved by global manufacturers.

The traction reflects this positioning. Reme-D is currently testing around 50,000 patients monthly across 92 hospitals and laboratories in Egypt, with more than 500,000 patients tested to date. Its footprint already extends beyond Egypt into Iraq, Sudan, and Kenya, with early-stage deployments in Nigeria and Libya.

One of the clearest use cases has emerged in blood bank screening. By replacing a two-step testing process with direct molecular diagnostics, Reme-D has reduced screening time by 70%, enabling faster and more comprehensive testing of donated blood.

At the same time, scaling remains operationally complex. While the company’s facility can produce up to 12 million tests per month, packaging constraints currently limit output to 130,000 units. Plans are underway to expand capacity fourfold by the second quarter of 2026.

The Ripple

Reme-D’s progress highlights a broader shift in how healthcare solutions are being built and scaled across the region.

For investors, it reinforces growing interest in deep tech and biotech in the wider MENA ecosystem. This is with a focus on solutions designed for frontier market conditions rather than adapted from developed markets.

Meanwhile, for healthcare systems, it introduces a pathway to reduce dependency on imported diagnostics while improving speed, cost efficiency, and clinical coverage.

For the biotech ecosystem, it signals that localized manufacturing combined with applied research can move beyond proof of concept into real commercial deployment.

What to Watch

The next phase is not just about expansion. It is about execution at scale.

Reme-D is preparing for full commercial entry into Nigeria and Libya while expanding its production capacity. At the same time, it is moving beyond infectious diseases into areas such as cancer diagnostics, genetic testing, and maternal health.

The underlying signal is clear. If the company can scale manufacturing and navigate regulatory complexity, room-temperature diagnostics could shift from a niche innovation into a foundational layer of healthcare delivery across multiple African markets.